Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Randomized, Open, Positive Controlled Clinical Study to Evaluate the Immunogenicity and Safety of Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell) in People Aged 18 Years and Over

Authors not listed

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 2022

Dysbiosis Human Randomized controlled trial

Abstract

Popular topic:A Clinical Study of Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell) Overall design:The study was designed as a randomized, open and controlled study. Study population: People aged 18 years and above and 6-15 months after the completion of basic immunization or 6-9 months after the completion of enhanced immunization with the new coronal prototype vaccine. Test groups:Study group；Control group；Observation group ①；Observation group ②

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-13 MST

Cite this

APA

Anonymous. (2022). A Randomized, Open, Positive Controlled Clinical Study to Evaluate the Immunogenicity and Safety of Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell) in People Aged 18 Years and Over. <em>Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.</em>. https://clinicaltrials.gov/study/NCT05574985

Vancouver

Anonymous. A Randomized, Open, Positive Controlled Clinical Study to Evaluate the Immunogenicity and Safety of Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell) in People Aged 18 Years and Over. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.. 2022.

BibTeX

@misc{anon2022ARando, title = {A Randomized, Open, Positive Controlled Clinical Study to Evaluate the Immunogenicity and Safety of Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell) in People Aged 18 Years and Over}, author = {Anonymous}, journal = {Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.}, year = {2022}, }